S&P Capital IQ also mentioned the SPDR S&P Biotech ETF (NYSEArca: XBI) in its note, although the research firm does not have a rating on that ETF.
“Of note, XBI’s top-10 holdings accounted for only 22.85% of total assets. Therefore, the robust 186% year-to-date return of these holdings contributed less to the fund’s 12-month total return of 40.7%. Overall, the fund’s constituents were 22% mega/large cap and 78% small/mid cap, as of September 30, 2013. XBI’s turnover is 61%, and its weighted average market cap is $9.3 billion, one third that of IBB,” said S&P Capital IQ.
XBI has dipped nearly 11% in the past month and is up 25.8% this year.
SPDR S&P Biotech ETF
